Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 66, Issue 2, Pages 184-192Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2015.05.030
Keywords
adherence; ezetimibe; low-density lipoprotein cholesterol; secondary prevention; statin therapy
Categories
Funding
- Amgen
- AstraZeneca
- Sanofi
- Aegerion
- Eli Lilly
- Genzyme
- GlaxoSmithKline
- Novartis
- Regeneron
Ask authors/readers for more resources
In addition to aggressive lifestyle and nonlipid risk factor modification, statin therapy improves cardiovascular disease outcomes following acute coronary syndromes. Despite established benefits of treatment, contemporary registries reveal substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in up to 40% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction in cardiovascular disease risk. (C) 2015 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available